Table 4.
Results of a stepwise backward deletion multiple linear regression analysis predicting Braak 1–3 -TSPO-BPND.
| Step | t | β | P | F | df | P | Adjusted R2 |
|---|---|---|---|---|---|---|---|
| Model 1 | 2.57 | 10, 14 | 0.05 | 0.396 | |||
| Age | 0.19 | 0.04 | 0.85 | ||||
| Sex | 1.68 | 0.37 | 0.11 | ||||
| Diagnosis (CN vs AD) | 3.02 | 0.64 | 0.009 | ||||
| ApoE4 positivity | 0.11 | 0.02 | 0.91 | ||||
| BMI | 0.81 | 0.14 | 0.43 | ||||
| CHI3L1 (ng/mL) | −0.43 | −0.09 | 0.68 | ||||
| MCP-1 (pg/mL) | 2.27 | 0.53 | 0.04 | ||||
| Clusterin (μg/mL) | 0.10 | 0.02 | 0.92 | ||||
| Fractalkine (pg/mL) | −0.14 | −0.04 | 0.89 | ||||
| sTREM2 (pg/mL) |
2.83 |
0.62 |
0.01 |
||||
| Model 2 | 3.06 | 9, 15 | 0.03 | 0.436 | |||
| Age | 0.18 | 0.03 | 0.86 | ||||
| Sex | 2.07 | 0.36 | 0.06 | ||||
| Diagnosis (CN vs AD) | 3.12 | 0.64 | 0.007 | ||||
| ApoE4 positivity | 0.10 | 0.02 | 0.92 | ||||
| BMI | 0.83 | 0.14 | 0.42 | ||||
| CHI3L1 (ng/mL) | −0.43 | −0.09 | 0.67 | ||||
| MCP-1 (pg/mL) | 2.34 | 0.53 | 0.03 | ||||
| Fractalkine (pg/mL) | −0.12 | −0.03 | 0.90 | ||||
| sTREM2 (pg/mL) |
3.12 |
0.62 |
0.007 |
||||
| Model 3 | 3.67 | 8, 16 | 0.01 | 0.470 | |||
| Age | 0.18 | 0.03 | 0.86 | ||||
| Sex | 2.14 | 0.36 | 0.05 | ||||
| Diagnosis (CN vs AD) | 3.3 | 0.64 | 0.004 | ||||
| BMI | 0.85 | 0.14 | 0.41 | ||||
| CHI3L1 (ng/mL) | −0.45 | −0.08 | 0.66 | ||||
| MCP-1 (pg/mL) | 2.44 | 0.53 | 0.03 | ||||
| Fractalkine (pg/mL) | −0.12 | −0.03 | 0.9 | ||||
| sTREM2 (pg/mL) |
3.24 |
0.62 |
0.005 |
||||
| Model 4 | 4.44 | 7, 17 | 0.006 | 0.501 | |||
| Age | 0.23 | 0.04 | 0.82 | ||||
| Sex | 2.25 | 0.35 | 0.04 | ||||
| Diagnosis (CN vs AD) | 4 | 0.62 | 0.001 | ||||
| BMI | 0.87 | 0.13 | 0.39 | ||||
| CHI3L1 (ng/mL) | −0.45 | −0.07 | 0.66 | ||||
| MCP-1 (pg/mL) | 2.85 | 0.52 | 0.01 | ||||
| sTREM2 (pg/mL) |
3.41 |
0.63 |
0.003 |
||||
| Model 5 | 5.46 | 6,18 | 0.002 | 0.527 | |||
| Sex | 2.4 | 0.36 | 0.03 | ||||
| Diagnosis (CN vs AD) | 4.12 | 0.62 | 0.001 | ||||
| BMI | 0.87 | 0.13 | 0.40 | ||||
| CHI3L1 (ng/mL) | −0.41 | −0.06 | 0.69 | ||||
| MCP-1 (pg/mL) | 3.02 | 0.52 | 0.007 | ||||
| sTREM2 (pg/mL) |
3.53 |
0.63 |
0.002 |
||||
| Model 6 | 6.82 | 5, 19 | 0.001 | 0.548 | |||
| Sex | 2.43 | 0.35 | 0.03 | ||||
| Diagnosis (CN vs AD) | 4.2 | 0.61 | <0.001 | ||||
| BMI | 0.85 | 0.12 | 0.41 | ||||
| MCP-1 (pg/mL) | 3.06 | 0.52 | 0.006 | ||||
| sTREM2 (pg/mL) |
3.64 |
0.61 |
0.002 |
||||
| Model 7 | 8.47 | 4, 20 | <0.001 | 0.554 | |||
| Sex | 2.30 | 0.32 | 0.03 | ||||
| Diagnosis (CN vs AD) | 4.15 | 0.59 | <0.001 | ||||
| MCP-1 (pg/mL) | 3.03 | 0.51 | 0.007 | ||||
| sTREM2 (pg/mL) | 3.60 | 0.60 | 0.002 |
For serum concentration of blood-based biomarkers the log10 conversion were performed.
R2 = Multiple regression value squared.
Abbreviations: TSPO, translocator protein: BPND, binding potential; CN, Cognitively normal; AD, Alzheimer's disease; BMI, body mass index; CHI3L1, chitinase 3-like protein-1; MCP-1, monocyte chemotactic protein 1; sTREM2, soluble triggering receptor expressed on myeloid cells 2.